Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248).

Abstract

6053 Background: Addition of concurrent anti-EGFR monoclonal antibody to radiotherapy alone did not worsen QOL (Curran 2007). We compared standard chemoradiotherapy (cRT) to bioradiotherapy (bRT). ...